MedCity News January 6, 2025
Orbis Medicines’ Series A round of funding was led by New Enterprise Associates. The startup is developing oral macrocyclic drugs for targets validated by blockbuster biologic medications that must be administered by injection.
Peptide drugs, such as the metabolic medicines Mounjaro and Zepbound from Eli Lilly, must be administered as injections. But the biotech industry has been pursuing ways to make peptides into pills, and the oral peptide research of startup Orbis Medicines now has Lilly as a financial backer.
Lilly is one of the investors in Orbis’s €90 million (about $93.4 million) Series A round announced Monday. The preclinical startup has not yet disclosed specific diseases for its drug research. But the Copenhagen-based company says it is focusing on...
Today's Sponsors
Today's Sponsor